<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03033225</url>
  </required_header>
  <id_info>
    <org_study_id>16-001243</org_study_id>
    <secondary_id>NCI-2019-07003</secondary_id>
    <secondary_id>16-001243</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT03033225</nct_id>
  </id_info>
  <brief_title>Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study</brief_title>
  <official_title>Phase II Study of EUS-Guided Verteporfin PDT in Solid Pancreatic Tumors (VERTPAC-02)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <brief_summary>
    <textblock>
      This phase II trial studies how well ultrasound-guided verteporfin photodynamic therapy works&#xD;
      for the treatment of patients with solid pancreatic tumors that cannot be removed by surgery&#xD;
      (unresectable) or pancreatic cancer that has spread to other places in the body (advanced).&#xD;
      Photodynamic therapy is a type of laser device that is guided by ultrasound imaging and used&#xD;
      in combination with the drug verteporfin that may be less invasive and as effective as&#xD;
      current treatment methods for patients with pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To show that endoscopic ultrasound (EUS)-guided photodynamic therapy (PDT) to the pancreas&#xD;
      is effective at direct ablation of advanced or locally advanced and small volume metastatic&#xD;
      pancreatic tumors in a multicenter setting.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the predictability of tumor necrosis as a function of delivered energy, based&#xD;
      on pre-PDT contrast computed tomography (CT) scans.&#xD;
&#xD;
      TERTIARY OBJECTIVE:&#xD;
&#xD;
      I. Evaluate the safety of chemotherapy given two days after PDT.&#xD;
&#xD;
      QUARTERNARY OBJECTIVE:&#xD;
&#xD;
      I. Demonstrate that cancer biomarkers in pre- versus (vs.) post-PDT are surrogate markers of&#xD;
      response.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive verteporfin intravenously (IV) and after 60 minutes undergo EUS-guided PDT.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 14 days, and at 3, 6, and 12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response</measure>
    <time_frame>12 months post photodynamic therapy (PDT)</time_frame>
    <description>To evaluate the predictability of tumor necrosis as a function of delivered energy, based on pre-PDT contrast computed tomography (CT) scans.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Pancreatic Carcinoma</condition>
  <condition>Locally Advanced Pancreatic Carcinoma</condition>
  <condition>Metastatic Pancreatic Carcinoma</condition>
  <condition>Pancreatic Neoplasm</condition>
  <condition>Stage II Pancreatic Cancer AJCC v8</condition>
  <condition>Stage IIA Pancreatic Cancer AJCC v8</condition>
  <condition>Stage IIB Pancreatic Cancer AJCC v8</condition>
  <condition>Stage III Pancreatic Cancer AJCC v8</condition>
  <condition>Stage IV Pancreatic Cancer AJCC v8</condition>
  <condition>Unresectable Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (verteporfin, EUS-guided PDT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive verteporfin IV and after 60 minutes undergo EUS-guided PDT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic Ultrasound</intervention_name>
    <description>Undergo EUS-guided PDT</description>
    <arm_group_label>Treatment (verteporfin, EUS-guided PDT)</arm_group_label>
    <other_name>endosonography</other_name>
    <other_name>EUS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Photodynamic Therapy</intervention_name>
    <description>Undergo EUS-guided PDT</description>
    <arm_group_label>Treatment (verteporfin, EUS-guided PDT)</arm_group_label>
    <other_name>PDT</other_name>
    <other_name>Photoradiation Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (verteporfin, EUS-guided PDT)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (verteporfin, EUS-guided PDT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verteporfin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (verteporfin, EUS-guided PDT)</arm_group_label>
    <other_name>Benzoporphyrin Derivative Monoacid Ring A</other_name>
    <other_name>BPD-MA</other_name>
    <other_name>Visudyne</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological/cytological diagnosis (Dx) of advanced or locally advanced or small&#xD;
             volume metastatic pancreatic cancer (PanCa) or other solid pancreatic tumor that is&#xD;
             not amenable to curative surgical resection, or the patient is unfit, or declines&#xD;
             surgery&#xD;
&#xD;
          -  Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2&#xD;
&#xD;
          -  Estimated life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Capable of giving written informed consent&#xD;
&#xD;
          -  Adequate biliary drainage (serum bilirubin &lt; 2.5 upper limit of normal [ULN]), with no&#xD;
             evidence of active uncontrolled infection (patients on antibiotics are eligible)&#xD;
&#xD;
          -  Women of child-bearing potential with a negative pregnancy test (qualitative serum&#xD;
             human chorionic gonadotropin [HCG]) prior to study entry AND must be using an adequate&#xD;
             contraception method, which must be continued for 1 week after PDT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For locally advanced patients, evidence of metastases other than lung or liver. For&#xD;
             lung metastases, greater than three lesions and any lesions greater than 5 cm are&#xD;
             excluded. For advanced patients, any metastasis is acceptable for enrollment&#xD;
&#xD;
          -  Porphyria&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Locally advanced disease involving &gt; 50% circumference of the duodenum or a major&#xD;
             artery within the treatment area&#xD;
&#xD;
          -  ECOG performance status 3 or 4&#xD;
&#xD;
          -  Previous treatment with curative intent for current disease within the past two weeks&#xD;
             (i.e. prior resection, radical radiotherapy or chemotherapy)&#xD;
&#xD;
          -  Any psychiatric disorder making reliable informed consent impossible&#xD;
&#xD;
          -  A history of documented hemorrhagic diathesis or coagulopathy on therapeutic&#xD;
             anticoagulation&#xD;
&#xD;
          -  History of prior or concomitant other malignancy that will interfere with the response&#xD;
             evaluation&#xD;
&#xD;
          -  Any evidence of severe or uncontrolled systemic diseases or laboratory finding that in&#xD;
             the view of the investigator makes it undesirable for the patient to participate in&#xD;
             the trial&#xD;
&#xD;
          -  Contrast allergy not amenable to treatment with steroids and antihistamines&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth K Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic in Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clincial Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth K. Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 24, 2017</study_first_submitted>
  <study_first_submitted_qc>January 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2017</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

